Compare KLA Corp. (KLAC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? KLA Corp. trades at $208.28 (market cap $261.92B), while State Street SPDR S&P Biotech ETF trades at $159.28. The key difference: KLA Corp. pays a 0.46% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, KLA Corp. nearer its low. Which is the better fit depends on your goals.
| KLAC | XBI | |
|---|---|---|
Market Cap | $261.92B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $301.71 | $164.28 |
52-Week Low | $84.39 | $86.92 |
Enterprise Value | $263.17B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $209.16, up 8.52% over 24 hours, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a 35.57% net income margin and 87.5% ROE, supported by a recent dividend hike and stock split. Analyst consensus is bullish with a $246.93 price target, though elevated valuation ratios like a P/E of 54.77 warrant caution.
Outlook remains positive driven by AI-driven semiconductor equipment demand, but risks include high valuation sensitivity and cyclical industry exposure. The stock offers growth potential with disciplined risk management advised given overbought technical conditions and macroeconomic uncertainties.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
